Stay on top of the latest research and practice
"RANKL -BONES, SEX, AND BREAST CANCER"
“WHY ARE WE FAILING TO CURE OVARIAN CANCER?”
Standard surgical treatment of endometrial cancer results in loss of fertility. In young women, conservative treatment of endometrial cancer aiming to preserve fertility is possible, but under strictly defined conditions.
The most up to date primary aspects in the management of young women affected by endometrial cancer will be presented in this session, including:
Risk factors and pathogenesis of Endometrial cancer in young women
Radical treatment of Endometrial cancer in young women
Conservative treatment of Endometrial cancer in young women
Management of recurrent disease
This will session will focus on the latest developments in the management of patients with pre- and frankly malignant gestational trophoblastic disease (GTD) as well as ovarian germ cell (MOGCT) and granulosa cell non-epithelial ovarian tumors, including the following key topics:
Recent developments in GTD and molar pregnancies
How can we eliminate deaths in high risk GTN?
What is the state-of-the-art for ovarian germ cell tumours?
Current and future directions for granulosa cell tumour management
Fertility Sparing Management in high risk epithelial ovarian cancer.
Can we safely use ovarian hyper-stimulation in infertile patients after FSS for epithelial tumors?
Fertility sparing management in cervical cancers between 2 and 4 cm: Radical Trachelectomy by Laparotomy or Neo-Adjuvant Chemotherapy?
How long hormonal treatment should be continued before deciding for hysterectomy in the fertility sparing management of endometrial cancer?
Diagnosis, Staging and preoperative workup
Surgery and adjuvant therapy in primary disease
Treatment of recurrent and metastatic disease
Cancer immunotherapy—treatments that harness and enhance the innate powers of the immune system to fight cancer, represent the most promising new cancer treatment approach since the development of the first chemotherapies.
The basic principles underlying immunotherapy, the host factors influencing the immune response to cancer and discuss the results of trials and ongoing studies evaluating new immuno-therapeutics in gynaecological cancers will be covered in this session, including:
Principles of immunotherapy
Challenges of immunotherapy: predictive factors and response criteria
Ovarian cancer immunotherapy trials
Not yet an ESGO member?
Join or renew today
Get notified on all news and activities right in your mailbox.
Opens in January, 2019.